Skip to main content

Table 6 Univariate and multivariate analysis of baseline factors associated with anatomic success and best corrected visual acuity improvement ≥15 letters. Factors associated with success in the univariate analysis at p ≤ 0.1 were included in the multivariate analysis

From: Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant

Factor

Anatomic success

BCVA gaining ≥ 15 letters

Univariate

Univariate

OR (95% CI)

P

OR (95% CI)

P

Sex

 Ref: Women

    

  Men

0.48 (0.15 to 1.52)

0.2103

2.55 (0.83 to 7.79)

0.1013

Agea

  > 73 years

2.2 (0.69 to 7.25)

0.1779

0.57 (0.19 to 1.71

0.3132

ME durationa

  > 32 days

0.40 (0.12 to 1.31)

0.1300

1.44 (0.48 to 4.29)

0.5148

ME Duration

 Ref: ≤ 30 days

    

   > 30 ≤ 60

0.27 (0.05 to 1.39)

0.1177

2.64 (0.57 to 12.25)

0.2555

   > 60

0.33 (0.09 to 1.22)

0.0955

0.91 (0.26 to 3.139

0.8745

ME duration

 Ref: ≤ 90 days

    

   > 90 days

0.39 (0.11 to 1.41)

0.1501

0.48 (0.12 to 1.98)

0.3082

RVO

 Ref: CRVO

    

  BRVO

1.88 (0.54 to 6.50)

0.3193

1.69 (0.46 to 6.23)

0.4287

ME Subtype

 Ref: SLRS

    

  CME

2.33 (0.12 to 43.79)

0.5711

1.00 (0.98 to 1.02)

0.9981

  SRD

2.50 (0.14 to 43.97)

0.5311

1.00 (0.98 to 1.02)

0.9981

Treatment status

 Ref: Naïve

    

  Previously treated

1.29 (0.41 to 4.07)

0.6613

0.36 (0.12 to 1.16)

0.0864

ELM status

 Ref: Non-disrupted

    

  Partially disrupted

0.73 (0.15 to 3.47)

0.6911

5.69 (0.62 to 52.34)

0.1248

  Disrupted

0.56 (0.11 to 2.72)

0.4692

19.5 (2.11 to 179.91)

0.0088

Baseline BCVAa

  > 60

0.66 (0.21 to 2.06)

0.4702

0.03 (0.00 to 0.21)

0.0007

DRIL

 Ref: No

    

  Yes

1.36 (0.39 to 4.74)

0.7280

2.84 (0.86 to 9.44)

0.0880

DRIL Location

 Ref: only INL/ONL

    

  Both affected

1.05 (0.33 to 3.33)

0.9340

0.36 (0.07 to 1.82)

0.2186

HRF

 Ref: < 10

    

  10–20

4.75 (1.11 to 20.39)

0.0361

0.96 (0.24 to 3.83)

0.9567

   > 20

2.60 (0.63 to 10.79)

0.1881

1.76 (0.43 to 7.19)

0.4313

HRF Location

 Ref: only INL/ONL

    

  Both affected

1.01 (0.31 to 3.32)

0.9830

0.72 (0.23 to 2.23)

0.5684

SRF

 Per μm thicker

1.00 (0.99 to 1.01)

0.4303

0.99 (0.99 to 1.01)

0.6753

SRF

  > 119 μm

2.97 (0.62 to 14.22)

0.1732

3.11(0.72 to 13.44)

0.1285

Cysts

 Ref: < 100

    

  100–200

1.00 (0.05 to 19.96)

1.000

1.00 (0.98 to 1.02)

0.9981

   > 200

3.67 (0.21 to 64.55)

0.3746

0.99 (0.99 to 1.01)

0.9979

Change in Septum M6

 Ref: No

    

  Yes

13.93 (2.78 to 69.83)

0.0014

1.97 (0.65 to 5.959

0.2300

  1. Multivariate analysis:
  2. • Anatomic success:
  3. ○ MD Duration > 60 days: OR: 0.34; 95% CI: 0.08 to 1.35; p = 0.1234
  4. ○ HRF 10–20: OR: 4.26; 95% CI: 0.88 to 25.60; p = 0.0712
  5. ○ Change in Septum month 6: OR: 1.09; 95% CI: 0.31 to 3.83; p = 0.8939
  6. • BCVA gaining ≥15 letters:
  7. ○ Baseline BCVA: OR: 0.04; 95% CI: 0.00 to 0.39; p = 0.0057
  8. ○ Treatment status: OR: 0.46; 95% CI: 0.19 to 1.96; p = 0.3003
  9. ○ ELM status (Disrupted): 5.78; 95% CI: 0.48 to 69.77; p = 0.1670
  10. ○ DRIL: OR: 1.29; 95% CI: 0.26 to 6.54; p = 0.7571
  11. Age: OR: 2.96; 95% CI: 0.92 to 9.57; p = 0.0695
  12. Duration of ME: OR: 2.65; 95% CI: 0.82 to 8.58; p = 0.1036
  13. Abbreviations: OR Odds ratio, CI Confidence interval, ME Macular edema, SLRS Sponge-like retinal swelling, CME Cystoid macular edema, SRD Serous retinal detachment, DRIL. Disorganization of inner retinal layer, INL Inner nuclear layer, ONL Outer nuclear layer, HRF Hyperreflective foci, SRF Subretinal fluid, M Month
  14. aReference group ≤ Median
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us